Wegovy for Heart Disease: What the SELECT Trial Changed
The first weight-loss medication ever approved for cardiovascular risk reduction. SELECT trial results, who qualifies, and why insurance coverage shifts under this indication.
In March 2024, the FDA approved Wegovy (semaglutide) for a second major indication: reducing the risk of cardiovascular death, heart attack, and stroke in adults with established cardiovascular disease and either obesity or overweight. It's the first weight-loss medication ever approved for cardiovascular risk reduction — and for patients who qualify, it may open insurance coverage that weight-loss framing alone does not.
The approval was based on SELECT, the largest cardiovascular outcomes trial ever completed in people with obesity and known heart disease. Here's what the data actually showed, who qualifies, and why this indication matters clinically and financially.
What SELECT Actually Measured
SELECT (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) was a multi-national, multi-center, randomized, double-blind, placebo-controlled superiority trial. 17,604 adults were randomized to Wegovy 2.4 mg weekly or placebo, added to standard cardiovascular care.
Inclusion criteria:
- Age 45 or older
- BMI ≥ 27 (overweight or obese)
- Established cardiovascular disease: prior myocardial infarction, prior stroke, or symptomatic peripheral arterial disease
- No type 1 or type 2 diabetes (critical distinction — SELECT specifically studied patients without diabetes to isolate the weight/CV effect from glucose effects)
Primary endpoint: time to first occurrence of a three-part composite MACE (Major Adverse Cardiovascular Events) — cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke.
The Results
| Outcome | Wegovy | Placebo | Reduction |
|---|---|---|---|
| MACE (primary) | 6.5% | 8.0% | 20% relative |
| All-cause mortality | — | — | 19% reduction |
| CV death | — | — | 15% reduction (NS) |
The 20% reduction in MACE was statistically significant (HR 0.80 [95% CI: 0.72, 0.90], p<0.001). The absolute risk reduction was 1.5% over a mean follow-up of 40 months. The all-cause mortality reduction (19%) was also significant. The 15% reduction in cardiovascular death specifically did not reach statistical significance (HR 0.85 [95% CI: 0.71, 1.01]), though it trended in the same direction.
Importantly, the benefit was consistent across subgroups — unchanged by age, sex, race, ethnicity, BMI at baseline, or level of renal function impairment.
This is a large, clinically meaningful effect. For reference, statins produce roughly 20–25% relative MACE reductions in similar patient populations. Wegovy's MACE benefit is comparable to some established cardiovascular medications — which is a significant bar for a drug originally developed for weight loss.
How the Mechanism Works (Or Might Work)
The exact mechanism of Wegovy's cardiovascular benefit is not established. The FDA and Novo Nordisk are explicit about this. The obvious candidate — weight loss driving reduced cardiovascular strain — is part of the story, but post-hoc analyses suggest it doesn't account for all of the benefit. Early MACE divergence between Wegovy and placebo appeared within weeks, before significant weight loss could plausibly drive the effect.
Other plausible contributors include:
- Direct anti-inflammatory effects (reductions in high-sensitivity C-reactive protein)
- Blood pressure reduction (systolic BP drops of 4–6 mmHg typical)
- Lipid profile improvements (triglyceride reductions, modest LDL improvements)
- Improved endothelial function (early animal and human data suggest direct vascular effects)
- Reduced visceral adiposity (beyond raw weight loss, the specific loss of metabolically active abdominal fat)
Ongoing research will clarify the contribution of each pathway. What matters clinically is that the benefit is real and measurable.
Who Qualifies Under the New Indication
Per the FDA label, Wegovy's cardiovascular indication covers adults with:
- BMI ≥ 27 (overweight or obesity)
- Established cardiovascular disease, defined as at least one of:
- Prior myocardial infarction (heart attack)
- Prior stroke
- Symptomatic peripheral arterial disease
Type 2 diabetes doesn't exclude you — it just wasn't part of the SELECT population. Patients with diabetes and cardiovascular disease often qualify under multiple Wegovy indications simultaneously.
Note what's not in the indication: cardiovascular risk factors alone (hypertension, dyslipidemia, family history) don't meet the threshold. The label requires established, documented disease — not risk of disease.
The Insurance Coverage Angle
This is where the CVD indication quietly changed the landscape. Many commercial insurance plans, self-funded employer plans, and Medicare Part D plans exclude GLP-1 medications when prescribed for weight loss. But cardiovascular disease is a standard covered indication across essentially every insurer — because cardiovascular outcomes drive enormous healthcare costs.
For a patient with BMI 30 and a prior heart attack who was denied Wegovy under a weight-loss framing, the cardiovascular indication may be the difference between:
- Denied: Weight-loss prescription, not a covered benefit
- Covered: Cardiovascular risk reduction with established MACE benefit documented in SELECT
The same medication, the same dose, the same patient — reframed through a different clinical lens. This is not gaming the system; it's accurately documenting the clinical indication that actually drives the prescription.
After the FDA's cardiovascular approval, CMS issued guidance clarifying that Medicare Part D plans can cover Wegovy for cardiovascular risk reduction in appropriate patients — because it's addressing a covered medical condition (cardiovascular disease), not weight loss, which remains excluded under Medicare's original Part D rules. Coverage specifics vary by plan.
Practical Implications for Patients
If You Have Established CVD
Bring this to your cardiologist or primary care provider. The conversation is no longer "can I get a weight-loss drug" — it's "I have cardiovascular disease and obesity, and there's now an FDA-approved medication proven to reduce my risk of another event."
Prior authorization requests filed under the CVD indication should include:
- Documentation of the qualifying cardiovascular event (MI, stroke, or symptomatic PAD)
- BMI documentation
- Current cardiovascular medications (to show standard-of-care baseline)
- Reference to the SELECT trial and the March 2024 FDA approval
If You Already Take Wegovy for Weight Loss
And you also have established CVD, consider asking your prescriber to update the clinical documentation to reflect both indications. This can protect coverage if your insurer tightens weight-loss restrictions in the future.
Need FDA-approved brand-name medication?
Sesame Care connects you with licensed U.S. physicians who prescribe brand-name Wegovy and Zepbound.
How It Compares to Other GLP-1s for CV Benefit
Wegovy is not the only GLP-1 with cardiovascular outcomes data, but it is currently the only one approved for cardiovascular risk reduction specifically in the obesity/overweight population without diabetes:
- Ozempic (semaglutide 1 mg): Approved for CV risk reduction in adults with type 2 diabetes and CVD (SUSTAIN-6 trial).
- Victoza (liraglutide): Approved for CV risk reduction in adults with type 2 diabetes and CVD (LEADER trial).
- Trulicity (dulaglutide): Approved for CV risk reduction in adults with type 2 diabetes with or without CVD (REWIND trial).
- Zepbound (tirzepatide): Not yet approved for a CV indication; the SURMOUNT-MMO trial is ongoing and may provide data in 2026–2027.
For patients with both diabetes and CVD, multiple GLP-1s carry CV labels. For patients with CVD and obesity but without diabetes, Wegovy is currently the only labeled option.
Side Effects and Risks
The SELECT trial confirmed the safety profile seen in earlier Wegovy weight-loss trials. Serious adverse events occurred in 33.4% of Wegovy-treated patients vs. 36.4% of placebo patients (notably, lower with the active drug). Discontinuation due to adverse events was higher with Wegovy (16%) than placebo (8%), driven primarily by gastrointestinal symptoms (10% vs. 2%).
Standard Wegovy warnings apply: pancreatitis, gallbladder disease, hypoglycemia (especially in patients on insulin or sulfonylureas), acute kidney injury, suicidal behavior or thinking monitoring, thyroid C-cell tumor warning (medullary thyroid carcinoma contraindication).
Questions for Your Cardiologist
- Given my history of [heart attack/stroke/PAD] and my BMI, do I qualify for Wegovy under the cardiovascular indication?
- How should this fit alongside my current cardiovascular medications (statin, beta-blocker, ACEi/ARB)?
- Will adding Wegovy change how we manage any of my existing prescriptions?
- What monitoring plan makes sense given my specific cardiac history?
- If my insurance initially denies coverage, what documentation should the appeal include?
The Bottom Line
The SELECT trial established Wegovy as genuinely cardioprotective — a 20% MACE reduction that's comparable to established cardiovascular medications. For patients with established CVD and obesity, this isn't a nice-to-have weight-loss drug; it's an evidence-based cardiovascular therapy that also addresses obesity. The insurance implications are significant: the CVD indication opens coverage pathways that weight-loss framing often closes. If you have qualifying CVD history and have been denied Wegovy before, the conversation with your provider and insurer should be different now.